1. Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med, 2006, 174(4): 373-378.
[2]
2. Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax, 2009, 64(2): 133-138.
[3]
3. Chaouat A, Weitzenblum E, Kessler R, et al. Sleep-related O2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. European Respiratory Journal, 1997, 10(8): 1730-1735.
[4]
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease. (2017 REPORT). Available at: http://www.goldcopd.org.
[5]
5. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and management of patients with COPD. Available at: http://dev.ersnet.org/275-guidelines.htm.
10. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest, 2015, 147(1): 266-274.
[11]
11. Jen R, Li YR, Owens RL, et al. Sleep in chronic obstructive pulmonary disease: evidence gaps and challenges. Can Respir J, 2016, 2016: 7947198.
[12]
12. Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis, 1992, 145(5): 1070-1076.
14. Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med, 2016, 375(7): 1617-1627.
[15]
15. Lacasse Y, Bernard S, Sériès F, et al. Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial. BMC Pulm Med, 2017, 17(1): 8.
